Hologic, Inc. (NASDAQ:HOLX) insider Sean S. Daugherty sold 4,001 shares of the firm’s stock in a transaction that occurred on Monday, May 10th. The shares were sold at an average price of $65.02, for a total transaction of $260,145.02. Following the completion of the transaction, the insider now owns 26,613 shares of the company’s stock, valued at approximately $1,730,377.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ HOLX traded down $1.52 during mid-day trading on Wednesday, reaching $62.95. 2,740,221 shares of the company’s stock were exchanged, compared to its average volume of 2,163,184. Hologic, Inc. has a 52 week low of $49.19 and a 52 week high of $85.00. The firm has a 50-day moving average price of $72.08 and a two-hundred day moving average price of $73.68. The firm has a market capitalization of $16.13 billion, a price-to-earnings ratio of 15.07, a price-to-earnings-growth ratio of 0.62 and a beta of 1.27. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.79 and a quick ratio of 1.47.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, April 28th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.62 by ($0.03). Hologic had a net margin of 29.53% and a return on equity of 45.24%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the prior year, the firm posted $0.57 earnings per share. The company’s revenue was up 103.4% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic, Inc. will post 7.17 EPS for the current fiscal year.
A number of brokerages recently issued reports on HOLX. Wells Fargo & Company raised their price objective on shares of Hologic from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, January 28th. Jefferies Financial Group raised their price target on shares of Hologic from $106.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, April 5th. BTIG Research raised their price target on shares of Hologic from $84.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, February 22nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lowered their price target on shares of Hologic from $90.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, May 5th. Finally, Robert W. Baird raised their price target on shares of Hologic from $84.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, March 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $85.44.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Featured Article: What does RSI mean?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.